Antiviral etiotropic chemicals: Efficacy against influenza A viruses A subtype H5N1

Voprosy Virusologii

Volumn 51, Issue 5, 2006, Pages 4-7

  Leneva, I A ^a   Shuster, A M ^a  

^a NONE

Author keywords

Antiviral agents; Influenza A viruses subtype H5N1

Indexed keywords

AVES; INFLUENZA A VIRUS; INFLUENZAVIRUS A; MURINAE;

EID: 33750690482     PISSN: 05074088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Avian Influenza A (H5N1) Infection in Humans. The Writing Committee of the WHO Consultation on Human Unfluenza A/ H5 // N. Engl. J. Med. - 2005. - Vol. 353. - P. 1374-1385.
2. st Centure: a central role for antivirals. - 2006, London, 19-20 January. - P. 32.
3. Barnett J. M., Gadman A., Gor D. et al. Zanamivir susceptibility. Monitoring and characterization of influenza vims clinical isolates obtained during phase II clinical effucacy studies // Antimicrob. Agents Chemother. - 2000. - Vol. 44. - P. 78-87.
4. Belshe R. B., Birk B., Newman F. et al. Resistence of influenza A viruses to amantadine and rimantadine. Results of one decade of surveillance // J. Infect. Dis. -1989. - Vol. 159. - P. 430-435.
5. Bright R., Medina M., Xu X. et al. Incidence of adamantine resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern // Lancet. - 2005. - Vol. 366. - P. 1175-1181.
6. CDC/WHO Avian Influenza Response Team. Outbreaks of Avian Influenza A (H5N1(In Asia and Interim Recommendations for Evaluation and Reporting of Suspected Cases-United States - 2004 // MMWR Morbid. Mortal. Wkly Rep. - 2004. - Vol. 53. - P. 97-100.
7. Claas E. C., Osterhaus A. D., van Beek R. et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus // Lancet. - 1998. - Vol. 351. - P. 472-477.
8. Crotty S., Cameron C., Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis? // J. Med. Chem. - 2002. - Vol. 80. - P. 86-95.
9. De Jong J. C., Class E. C., Osterhaus A. D. M. E. et al. A pandemic warning? // Nature. - 1997. - Vol. 389. - P. 554.
10. FDA. Antiviral Drug Advisory Committee. - Gaithersburg; 2002. - P. 1-266.
11. Glushkov R. G. Arbidol. Antiviral, immunostimulant, interferon inducer. // Drug of the Future. - 1992. - N 17. - P. 1079-1081.
12. Govorkova E. A., Leneva I. A., Goloubeva O. G. et al. Comparison of the efficacy of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses // Antimicrob. Agents Chemother. - 2001. - Vol. 45. - P. 2723-2732.
13. Gubareva L. V., Bethell R. C., Hart G. J. et al. Characterization of mutants of influenza A virus selected with the NA inhibitor 4-guanidino- Neu5Ac2en // J. Virol. - 1996. - Vol. 70. - P. 1818-1827.
14. Gubareva L. V., Robinson M. J., Bethell R. C. et al. Catalyc and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en // J. Virol. - 1997. - Vol. 71. - P. 3385-3390.
15. Hay A. J., Wolstenholme A. J., Skehel J. J. et al. The molecular basis of the specific antiinfluenza action of amantadine // EMBO J. - 1985. - Vol. 4. - P. 3021-3024.
16. Hay A. Amantadine and rimantadine-mechanisms // Antiviral Drug Resistance / Ed. D. Richman. - Chichester, 1996. - P. 44-58.
17. Hayden F. WHO Guidelines in the Use of Vaccines and Antivirals during Influenza. Annex 5-Considerations for the User of Antivirals during an Influenza pandemic, Geneva, 2-4 October, 2002.
18. Kiso M., Mitamura K., Sakai-Tagawa Y. et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study // Lancet. - 2004. - Vol. 364. - P. 759-765.
19. Le Q., Kiso M., Simeya X. et al. Avian flu: isolation of drug-resistant H5N1 virus // Nature. - 2005. - Vol. 438. - P. 754.
20. Leneva I., Roberts N., Govorkova E. et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza virus // Antiviral Res. - 2000. - Vol. 48. - P. 101-115.
21. Leneva I., Goloubeva O., Fenton R. et al. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals // Antimicrob. Agents Chemother. - 2001. - Vol. 45. - P. 1216-1224.
22. th International Congress of Virology, Paris, 2002. - Abstr. 1077.
23. Macdonald S., Cameron R., Demaine D. et al. Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza // J. Med. Chem. - 2005. - Vol. 48. - P. 2964-2971.
24. McKimm-Breshlin J., Trivedi T., Hampson A. et al. Neuraminidase sequence analyses and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir // Antimicrob. Agents Chemother. - 2003. - Vol. 47. - P. 2264-2272.
25. Peiris M., Yuen K. Y., Leung C. W. et al. Human infection with influenza H9N2 // Lancet. - 1999. - Vol. 354. - P. 916-917.
26. st Centure: A Central Role for Antivirals. - 2006, London, 19-20 January. - P. 33.
27. Sidwell R., Bailey K., Wong M. et al. In vitro and in vivo influenza virus-inhibitory effects of viramidine // Antiviral Res. - 2005. - Vol. 68. - P. 10-17.
28. Subbarao K., Klimov A., Katz J. et al. Characterization of an avian influenza A (H5N1) virus isolated from child with fatal respiratory illness // Science. - 1998. - Vol. 279. - P. 393-396.
29. Yem H., Monto A., Webster R. et al. // Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice // J. Infect. Dis. - 2005. - Vol. 192. - P. 665-672.